ArticleBMC infectious diseases2026
HBsAg loss in recipients with chronic hepatitis B after allogeneic hematopoietic stem-cell transplantation: a retrospective cohort study exploring kinetic dynamics.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic hepatitis B virus (HBV) infection poses a significant challenge in immunocompromised populations, particularly among hematologic malignancy patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, data regarding the mechanisms underlying this alteration have only been partially reported. This study aimed to explore the kinetics of HBsAg and the potential for achieving functional cure (HBsAg loss) after allo-HSCT by analyzing longitudinal quantitative data from a complete cohort in patients with chronic HBV and hematologic malignancies.
methodsA retrospective cohort study was conducted at the First Affiliated Hospital of Xi’an Jiaotong University from January 2013 to December 2023. Among the 622 consecutive allo-HSCT recipients, 15 patients with chronic HBV infection were included. Virological marker (HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc) and HBV DNA levels were monitored longitudinally before and after transplantation according to a standard protocol (baseline, weekly for the first month, monthly for 6 months, then every 3 months).The primary endpoint was HBsAg seroconversion, with exploratory outcome measures including HBV reactivation, cirrhosis decompensation, and mortality.
resultsAmong the 15 patients, two (13.3%) achieved HBsAg seroconversion at 6 months and 12 months post transplantation. Both patients were HBeAg-negative, had undetectable HBV DNA before transplantation, and maintained HBsAg clearance during extended follow-up, with one patient discontinuing antiviral therapy. The remaining 13 patients (86.7%) remained HBsAg positive. Comparative analysis of the entire cohort’s longitudinal quantitative HBsAg data revealed distinct kinetic patterns between the two subgroups, providing preliminary insights into differential clearance trajectories. Non-liver-related causes mortality was observed, although four patients (26.7%) died from nonliver-related causes, primarily severe pneumonia or underlying hematologic disease. The mean follow-up duration was 165 weeks, with a median follow-up of 189 weeks for survivors.
conclusionThis exploratory cohort study, utilizing complete longitudinal quantitative data, demonstrates that HBsAg clearance occurred in 2 of 15 patients post-HSCT and provides a comparative analysis of HBsAg kinetics between patients with and without clearance. These findings offer preliminary mechanistic clues and highlight the potential of allo-HSCT, alongside antiviral prophylaxis, as a safe context for exploring HBV functional cure in this high-risk population. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.